Abstract
Hyperhomocysteinemia (HHcy) has been recognized as a risk factor for developing Alzheimers disease (AD). However, its underlying molecular mechanisms are still elusive. Here we show that HHcy induces an elevation of amyloid beta (Aβ) levels and deposition, as well as behavioral impairments, in a mouse model of AD-like amyloidosis, the Tg2576 mice. This elevation is not associated with significant change of the steady state levels of the Aβ precursor protein (APP), β- or α-secretase pathways, nor with the Aβ catabolic pathways. By contrast, HHcy significantly reduces glycogen synthase kinase 3 (GSK3) Ser21/9 phosphorylation, but not total GSK3 protein levels. Similar results are obtained in brains homogenates from a genetic mouse model of HHcy. In vitro studies show that homocysteine increases Aβ formation, reduces phosphorylated GSK3 levels, without changes in total APP and its metabolism, and these effects are prevented by selective GSK3 inhibition. Overall, these data support a potential link between GSK3 and the pro-amyloidotic effect of HHcy in vivo and in vitro.
Keywords: Amyloid metabolism, amyloid β, Tg2576 mice, glycogen synthase kinase 3
Current Alzheimer Research
Title: Diet-Induced Hyperhomocysteinemia Increases Amyloid-β Formation and Deposition in a Mouse Model of Alzheimers Disease
Volume: 7 Issue: 2
Author(s): J.-M. Zhuo, G. S. Portugal, W. D. Kruger, H. Wang, T. J. Gould and D. Pratico
Affiliation:
Keywords: Amyloid metabolism, amyloid β, Tg2576 mice, glycogen synthase kinase 3
Abstract: Hyperhomocysteinemia (HHcy) has been recognized as a risk factor for developing Alzheimers disease (AD). However, its underlying molecular mechanisms are still elusive. Here we show that HHcy induces an elevation of amyloid beta (Aβ) levels and deposition, as well as behavioral impairments, in a mouse model of AD-like amyloidosis, the Tg2576 mice. This elevation is not associated with significant change of the steady state levels of the Aβ precursor protein (APP), β- or α-secretase pathways, nor with the Aβ catabolic pathways. By contrast, HHcy significantly reduces glycogen synthase kinase 3 (GSK3) Ser21/9 phosphorylation, but not total GSK3 protein levels. Similar results are obtained in brains homogenates from a genetic mouse model of HHcy. In vitro studies show that homocysteine increases Aβ formation, reduces phosphorylated GSK3 levels, without changes in total APP and its metabolism, and these effects are prevented by selective GSK3 inhibition. Overall, these data support a potential link between GSK3 and the pro-amyloidotic effect of HHcy in vivo and in vitro.
Export Options
About this article
Cite this article as:
Zhuo J.-M., Portugal S. G., Kruger D. W., Wang H., Gould J. T. and Pratico D., Diet-Induced Hyperhomocysteinemia Increases Amyloid-β Formation and Deposition in a Mouse Model of Alzheimers Disease, Current Alzheimer Research 2010; 7 (2) . https://dx.doi.org/10.2174/156720510790691326
DOI https://dx.doi.org/10.2174/156720510790691326 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Trials in Human Transmissible Spongiform Encephalopathies: Recent Advances and Problems to Address
Infectious Disorders - Drug Targets Transgenic Mice as a Model for Alzheimers Disease
Current Alzheimer Research Guggulsterone for Chemoprevention of Cancer
Current Pharmaceutical Design Medicinal and Beneficial Health Applications of Tinospora cordifolia (Guduchi): A Miraculous Herb Countering Various Diseases/Disorders and its Immunomodulatory Effects
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Current Clinical Applications of Botulinum Toxin
Current Pharmaceutical Design Bacteriophage - A Common Divergent Therapeutic Approach for Alzheimer's Disease and Type II Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Meet the Editorial Board Member
Current Neuropharmacology Recent Topics on Pharmacotherapy for Amphetamine-Type Stimulants Abuse and Dependence
Current Drug Abuse Reviews Alzheimer: A Decade of Drug Design. Why Molecular Topology can be an Extra Edge?
Current Neuropharmacology Perception of Symptoms in Hypertensive Patients and the Relevance to the Application of Anti- Hypertensive Drug Therapy
Current Pharmaceutical Design Drug Delivery Systems for Brain Tumor Therapy
Current Pharmaceutical Design Senescence of the Brain: Focus on Cognitive Kinases
Current Pharmaceutical Design Cooling the Injured Brain: How Does Moderate Hypothermia Influence the Pathophysiology of Traumatic Brain Injury
Current Pharmaceutical Design Beneficial Effects of Choline Alphoscerate on Amyloid-β Neurotoxicity in an In vitro Model of Alzheimer’s Disease
Current Alzheimer Research Chronic Obstructive Pulmonary Disease and Asthma and the Risk of Mild Cognitive Impairment and Dementia: A Population Based CAIDE Study
Current Alzheimer Research Segmentation of Brain MRI for Detecting Alzheimer's Disease
Current Medical Imaging The Aging of the Adaptive Immune System
Current Immunology Reviews (Discontinued) Methylated MicroRNA Genes of the Developing Murine Palate
MicroRNA Sensory-Dependent Knowledge in Young and Elderly Adults: Argument from the Cross-Modal Priming Effect
Current Aging Science Adenosine A2A Receptor Antagonists and Parkinsons Disease: State of the Art and Future Directions
Current Pharmaceutical Design